Ultrasound Historical Financial Summary
Unique Portfolio Across Molecular Medicine
Increased Activity in Nuclear Medicine (NM)
Cancer: #2 cause of death globally
(GE HealthCare
The Future of Molecular Imaging (MI) is Personal
Total MI for Theranostics -
GE's comprehensive & industry-leading solution
62%-a) surge in cancer incidence
TracerCenter
FASTlab 2
Omni Platform
StarGuide
Q.Thera Al-c)
in the next two decades
Discovery: Cyclotron, radiochemistry to drive
production of new tracers.
32%-b) annual growth in
Radiotherapeutics from 2020 to 2031 in
NM markets with approvals of new drugs.
Diagnosis: High-resolution digital PET/CT for
staging and re-staging tumors
Precision care leading to an expansion of clinical guidelines
Across oncology, neurology and cardiology
(a Source: https://www.cancer.org/research/cancer-facts-statistics/global.html
(b - Projected
(c 510(k) pending
Treatment: Powerful digital SPECT/CT with
advanced Al-powered clinical apps
© 2022, General Electric Company. Proprietary information. All rights reserved.
41View entire presentation